Very thoughtful – thanks for sharing. When people ask why the biotech markets have been so stagnant, I reflexively say something about interesting rates. But I think that's largely cope and the real reasons are the ones you mention: our target discovery methods are no match for complex disease biology and we're running out of easy targets. Excited for your vision.
Very thoughtful analysis, although the timelines for the adoption of a new “systems biology” approach regarding drug discovery are pretty depressing. I’d be curious if the author is aware of the prevalence of translational models that can accurately recapitulate human disease assets. It’s often been argued that one of the reasons for poor and stagnant clinical trial success is the lack of valid animal models in many therapeutic areas (cancer being a prime example here).
Very thoughtful – thanks for sharing. When people ask why the biotech markets have been so stagnant, I reflexively say something about interesting rates. But I think that's largely cope and the real reasons are the ones you mention: our target discovery methods are no match for complex disease biology and we're running out of easy targets. Excited for your vision.
Great summary, totally agree! I've been building with this in mind for years.
Very thoughtful analysis, although the timelines for the adoption of a new “systems biology” approach regarding drug discovery are pretty depressing. I’d be curious if the author is aware of the prevalence of translational models that can accurately recapitulate human disease assets. It’s often been argued that one of the reasons for poor and stagnant clinical trial success is the lack of valid animal models in many therapeutic areas (cancer being a prime example here).